This trial is evaluating whether Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody will improve 1 primary outcome and 3 secondary outcomes in patients with Non-Small Cell Lung Carcinoma (NSCLC). Measurement will happen over the course of After surgery (approximately 10 weeks).
This trial requires 181 total participants across 1 different treatment group
This trial involves a single treatment. Atezolizumab (MPDL3280A), An Engineered Anti-PD-L1 Antibody is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"There are probably more people getting carcinoma, non-small-cell lung than clinicians think, accounting for the greater proportions of people with the disease, and these estimations are higher than estimates previously published in the United States." - Anonymous Online Contributor
"For the first time, we identified the age distribution of patients diagnosed with carcinoma, non-small-cell lung. We also have found that almost 85% of all carcinomas were diagnosed at a body mass index (BMI) of ≤18. Given these data, clinicians will need to be attentive when addressing age-related health concerns for their patients during their health assessment and treatment." - Anonymous Online Contributor
"Signs of C&NSCLC include weight loss, coughing up blood, and shortness of breath. Other symptoms may include coughing up blood, and chest pain and shortness of breath.\n" - Anonymous Online Contributor
"Carcinoma of the lung is strongly associated with smoking, a history of bronchiectasis and unexplained death of a first-degree relative. Carcinoma of the large airways is strongly associated with the presence of a family history of lung cancer, male sex, smoking and bronchiectasis." - Anonymous Online Contributor
"It is conceivable that a cure will be found for NSCLC, but it would likely have to involve one of the available targeted therapies and only a small minority of patients." - Anonymous Online Contributor
"Non-small-cell [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) (NSCLC) is the most lethal form of cancer among Caucasians, accounting for about 25% of lung cancer in the US population. Lung cancer appears to be a product of multiple etiologies, including genetic predisposition, tobacco exposure, diet, and environmental factors. Smoking is a predominant environmental risk factor for lung cancer in both men and women." - Anonymous Online Contributor
"The most common treatment for the cancer is surgery. When the disease is in the local region, surgery is a definitive therapy; if it moves the disease into another location, chemotherapy is the treatment of choice for the cancer. The disease spreads to distant and other sites of the body, then radiation therapy is the therapy of choice. Radiation therapy is also a way of looking after the cancer." - Anonymous Online Contributor
"The 3-year survival rate for non-small-cell lung cancer is 27.2±4.5%, and the 5-year survival rate is 15.6±6.0%. Survival rates based on the stage of spread of disease at the time of diagnosis are as follows: stage I and 2, 31.8% after 3 years; stage III and IV, 14.8% after 3 years." - Anonymous Online Contributor
"The risk of developing malignant diseases is markedly increased among subjects presenting to a ENT-Head and Neck Surgery Unit with nasal polyp or adenoid hypertrophy." - Anonymous Online Contributor
"Atelezolizumab, a mutant anti-PD-1 antibody, may represent a favorable treatment option for patients with a variety of NSCLC, with many patients having only mild symptoms." - Anonymous Online Contributor
"The overall impact on survival of patients eligible for clinical trials for carcinoma, non-small-cell lung was not impacted by the fact study results were published, although study completion was associated with improved survival (hazard ratio <1). Clinical trials for cancer, especially lung cancer, deserve to be funded for the improvement that treatment of cancer trials could provide to millions of patients." - Anonymous Online Contributor
"For these indications to be considered, the patients enrolled in these studies (both PD-L1 negative and PD-L1-expressing), and the indications are limited rather than the overall results. The following results have shown the PD-1/PD-L1 checkpoint as a target of immune response after the activation of T and B cells." - Anonymous Online Contributor